Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

• Published in: New England Journal of Medicine Vol. 384; no. 20; pp. 1885 - 1898
• Main Authors: Madhi, Shabir A, Baillie, Vicky, Cutland, Clare L, Voysey, Merryn, Koen, Anthonet L, Fairlie, Lee, Padayachee, Sherman D, Dheda, Keertan, Barnabas, Shaun L, Bhorat, Qasim E, Briner, Carmen, Kwatra, Gaurav, Ahmed, Khatija, Aley, Parvinder, Bhikha, Sutika, Bhiman, Jinal N, Bhorat, As’ad E, du Plessis, Jeanine, Esmail, Aliasgar, Groenewald, Marisa, Horne, Elizea, Hwa, Shi-Hsia, Jose, Aylin, Lambe, Teresa, Laubscher, Matt, Malahleha, Mookho, Masenya, Masebole, Masilela, Mduduzi, McKenzie, Shakeel, Molapo, Kgaogelo, Moultrie, Andrew, Oelofse, Suzette, Patel, Faeezah, Pillay, Sureshnee, Rhead, Sarah, Rodel, Hylton, Rossouw, Lindie, Taoushanis, Carol, Tegally, Houriiyah, Thombrayil, Asha, van Eck, Samuel, Wibmer, Constantinos K, Durham, Nicholas M, Kelly, Elizabeth J, Villafana, Tonya L, Gilbert, Sarah, Pollard, Andrew J, de Oliveira, Tulio, Moore, Penny L, Sigal, Alex, Izu, Alane
• Format: Journal Article Web Resource
• Language: English
• Published: United States Massachusetts Medical Society 20.05.2021
• Subjects: Adenoviridae; Adolescent; Adult; Adverse events; Antibodies; Antibodies, Neutralizing - blood; Antibodies, Neutralizing - physiology; ChAdOx1 nCoV-19; Clinical trials; Coronaviruses; COVID-19; COVID-19 - epidemiology; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 Serological Testing; COVID-19 vaccines; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - adverse effects; COVID-19 Vaccines - immunology; Disease resistance; Double-Blind Method; Genomes; HIV; Human immunodeficiency virus; Humans; Immunogenicity, Vaccine; Infections; Laboratories; Middle Aged; Mutation; Original; Placebos; Safety; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Sodium chloride; South Africa; T-Lymphocytes - physiology; Treatment Failure; Vaccine efficacy; Vaccine Potency; Vaccines; Viruses; Young Adult; South Africa; United Kingdom > UK; Brazil
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa2102214

A double-blind randomized trial in South Africa documented poor efficacy of two doses of the ChAdOx1 nCoV-19 vaccine against the B.1.351 variant of SARS-CoV-2 that emerged in South Africa. Infections occurred in 3.2% of placebo recipients and in 2.5% of vaccine recipients. Thirty-nine of the 42 virus isolates were the B.1.351 variant. None of the cases led to hospitalization or death.